828 results on '"Ruppert, A. S."'
Search Results
52. Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
53. Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
54. Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance
55. Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
56. Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
57. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
58. Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma
59. Half Title Page, Title Page, Copyright, Dedication
60. 4 The Consumer City
61. 1 The Good City
62. 3 The Secure City
63. 2 Making Yonge-Dundas Good
64. 5 The Aesthetic City
65. List of Tables and Maps
66. 7 Making the Good City
67. 8 Yonge-Dundas Made Good?
68. Acknowledgments
69. Contents
70. Appendix A: List of Exhibits
71. Bibliography
72. 6 The Governable City
73. Notes
74. Appendix B
75. Index
76. Illustration Credits
77. Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
78. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
79. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma
80. Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]
81. Development of a distributed international patient data registry for hairy cell leukemia
82. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
83. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
84. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
85. A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
86. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
87. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
88. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
89. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib
90. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
91. Strategies to Account for Design Misspecifications in Randomized Controlled Trials
92. Compendium of Resources on Teacher Mobility. A Report of the SHEEO Project 'Enhancing the Teaching Profession: The Importance of Mobility to Recruitment and Retention.'
93. Improving Pension Portability for K-12 Teachers. A Report of the SHEEO Project 'Enhancing the Teaching Profession: The Importance of Mobility to Recruitment and Retention.'
94. Green Costs Less
95. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL
96. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
97. Focus on the Customer: A New Approach to State-Level Accountability Reporting and Processes for Higher Education.
98. Legislative Views on Higher Education Technology Use.
99. The Prescribed Pediatric Center: A Medical Day Treatment Program for Children with Complex Medical Conditions.
100. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.